证券代码：603590 证券简称：康辰药业 公告编号：临 2025-037 北京康辰药业股份有限公司 具体内容详见公司同日于指定信息披露媒体披露的《关于变更公司注册资本 暨修订<公司章程>的公告》 第四届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 北京康辰药业股份有限公司（以下简称"公司"）第四届董事会第十八次会 议于 2025 年 8 月 6 日以电子邮件方式通知全体董事，于 2025 年 8 月 11 日以传 签方式形成有效决议。本次会议召集人为董事长刘建华先生，会议应当参加表决 的董事 9 名，实际参加表决的董事 9 名。本次会议的参与表决人数及召开程序符 合《公司法》和《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 1、审议通过《关于变更公司注册资本暨修订<公司章程>的议案》 表决结果：9 票同意、0 票反对、0 票弃权。 该议案尚需提交公司股东大会审议通过。 2、审议通过《关于提请召开 2025 年第二次临时股东大会的议案》 具体内容详见公司同日于指 ...

Core Viewpoint - The article highlights the performance of various sectors in the stock market, particularly focusing on the top-performing stocks in July and the anticipated trends for August, with a strong emphasis on the electronic, basic chemical, pharmaceutical, and mechanical equipment industries [1][4][9]. Summary by Sections July Performance - In July, the innovative drug sector showed remarkable performance, with Kangchen Pharmaceutical leading with a 107% monthly increase, followed by Borui Pharmaceutical at 82%, and Kangfang Biotech at 68% [2][3]. - The electronic and communication sectors also had notable performers, such as Dongshan Precision with a 55% increase and Tonglian Precision with a 50% increase [3]. - Over 30 brokerage firms reported a monthly return of over 5% from their recommended stocks, with six firms exceeding 10% [3]. August Outlook - As of August, the latest stock recommendations show a strong focus on electronic, basic chemical, pharmaceutical, and mechanical equipment sectors [4][9]. - Dongfang Caifu is highlighted as the most popular stock, recommended by six institutions, with expectations of significant price increases in the securities sector [4][9]. - Luoyang Molybdenum is also recommended, with projections of continued growth in copper production and high copper prices leading to increased revenue and profit [5]. Market Predictions - Analysts predict that the market may reach new highs in the second half of the year, driven by sustained capital inflows and opportunities in emerging industries [9][10]. - The focus for investment strategies includes sectors benefiting from "anti-involution" policies, such as coal, steel, and photovoltaic industries, as well as technology growth areas like AI and innovative pharmaceuticals [9][10].

Core Viewpoint - The A-share market showed a strong recovery in July, with all 30 broker stock combinations recorded positive returns, indicating a favorable investment environment [1][4]. Group 1: July Stock Performance - The top-performing stock in July was Kangchen Pharmaceutical, recommended by Ping An Securities, with a remarkable increase of 106.74% [3][4]. - Other notable stocks included Bori Pharmaceutical (82.05% increase) and Kangfang Biotech (68.13% increase), recommended by Dongwu Securities and Northeast Securities respectively [3][4]. - Stocks such as Yuandong Biological, Dongshan Precision, and Jitu Express-W also saw increases exceeding 50% [4]. Group 2: Broker Performance - Ping An Securities led the broker stock combinations with a return of 16.57% in July, followed by Kaiyuan Securities (13.57%) and Caitong Securities (12.93%) [5]. - Other brokers like China Merchants Securities, Great Wall Securities, and Galaxy Securities also achieved returns above 10% [5]. Group 3: August Investment Strategy - Brokers are adopting an aggressive strategy for August, focusing on technology growth stocks and cyclical stocks benefiting from mid-year performance [7][11]. - The market is expected to continue its upward trend driven by optimistic expectations regarding corporate ROE recovery [11]. Group 4: Recommended Stocks for August - The most frequently recommended stocks for August include Dongfang Caifu, Muyuan Foods, and Wanhua Chemical, each receiving four recommendations from different brokers [13][14]. - Dongfang Caifu is expected to benefit from a bullish trend in the securities sector, while Muyuan Foods is projected to maintain stable profits amid rising pig prices [13][14].

Group 1 - The overall performance of brokerage "gold stocks" in July was positive, with all 30 brokerage combinations showing gains [2][4] - Ping An Securities' gold stock combination led with a return of 16.57%, followed by Kaiyuan Securities at 13.57% and Caitong Securities at 12.93% [4][5] - The top-performing individual stock was Kangchen Pharmaceutical, recommended by Ping An Securities, which saw a remarkable increase of 106.74% in July [2][3] Group 2 - Other notable stocks included Bori Pharmaceutical with an 82.05% increase and Kangfang Biotech with a 68.13% increase, both recommended by East Wu Securities and Northeast Securities respectively [2][3] - Stocks recommended by Ping An Securities, such as Yuandong Biological, also performed well, with increases exceeding 50% [2] - As of August 1, several brokerages, including Guojin Securities and Guohai Securities, have launched their gold stock combinations for August, focusing on technology growth stocks and cyclical stocks benefiting from mid-year performance [6] Group 3 - The most frequently recommended stocks for August included Dongfang Caifu, Muyuan Foods, and Wanhua Chemical, each receiving four recommendations from different brokerages [9][11] - Guohai Securities highlighted Dongfang Caifu's potential for a significant upward trend in the securities sector over the next two months [10] - Guojin Securities emphasized Muyuan Foods' leading position in pig farming, projecting stable profits amid rising pork prices [10]

Core Viewpoint - The article highlights the strong performance of brokerage "gold stocks" in July, with all 30 brokerage gold stock combinations showing positive returns, indicating a robust recovery in the A-share market [2][9]. Brokerage Performance - Ping An Securities' gold stock combination achieved the highest return of 16.57% in July, followed by Kaiyuan Securities at 13.57% and Caitong Securities at 12.93% [3][9][10]. - Notably, all brokerage gold stock combinations recorded positive returns, with several brokerages, including China Merchants Securities and Galaxy Securities, also exceeding 10% returns [9][10]. Top Performing Stocks - The best-performing stock was Kangchen Pharmaceutical, recommended by Ping An Securities, which surged by 106.74% in July [4][6]. - Other notable stocks included Borui Pharmaceutical (82.05%), Kangfang Biotech (68.13%), and Yuandong Biotech (56.60%), all showing significant monthly gains [6][7]. August Strategy - Brokerages are adopting an aggressive strategy for August, focusing on technology growth stocks and cyclical stocks benefiting from mid-year performance reports [12][15]. - The market outlook is optimistic, driven by expectations of recovering corporate ROE and a favorable policy environment, suggesting a continued upward trend in A-shares [15]. Common Recommendations - Several stocks received multiple recommendations from brokerages for August, including Dongfang Caifu, Muyuan Foods, and Wanhua Chemical, each recommended by four different brokerages [16][19]. - The rationale for recommending Dongfang Caifu includes the potential for the securities sector to enter a main upward trend, while Muyuan Foods is recognized for its leading position in the pig farming industry [16][19].

Group 1 - The innovative drug sector is experiencing a significant rise, with companies such as Shutaishen (300204), Rejing Bio, Kangchen Pharmaceutical (603590), Fuyuan Pharmaceutical (601089), and Yuekang Pharmaceutical reaching historical highs during trading [1] - Qizheng Tibetan Medicine (002287) has achieved three consecutive trading limit increases, while Hanshang Group (600774) has seen two consecutive limit increases [1] - Other companies including Lianhuan Pharmaceutical (600513), Guizhou Bailing (002424), Anglikang (002940), Xintian Pharmaceutical (002873), and Zhongsheng Pharmaceutical (002317) have also hit trading limits, with Weikang Pharmaceutical (300878) and Dajia Weikang (301126) rising over 10% [1]

证券之星消息，7月31日生物制品板块较上一交易日上涨0.05%，安科生物领涨。当日上证指数报收于 3573.21，下跌1.18%。深证成指报收于11009.77，下跌1.73%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300009 | 安科生物 | 12.11 | 20.02% | 330.56万 | | 38.34亿 | | 688136 | 科兴制药 | 53.25 | 13.15% | 19.24万 | | 9.56亿 | | 688278 | 特宝生物 | 91.33 | 7.46% | 12.10万 | | 11.04亿 | | 300841 | 康华生物 | 77.47 | 5.76% | 11.37万 | | 8.67亿 | | 688293 | 奥浦迈 | 60.50 | 5.38% | 2.60万 | | 1.58亿 | | 301393 | 吴帆生物 | 61.69 | 4.86% | 7.17万 | | 4.37亿 | ...

7月30日，三大指数涨跌不一，截至收盘，沪指涨0.17%，深成指跌0.77%，创业板跌1.62%，科创50指数跌1.11%，两市超1600只个股上涨，沪深两市今日成 交额约1.84万亿元。 影视板块表现出众，堪称今日最靓的仔，其中，幸福蓝海（300528.SZ）涨停20%，该公司5天内录得4个大号涨停板，累计上涨113%。此外，慈文传媒 （002343.SZ）、金逸影视（002905.SZ）涨10%，北京文化（000802.SZ）涨超9%。 据悉，幸福蓝海参与出品的影片《南京照相馆》，上映后连续多日蝉联票房冠军。灯塔专业版数据显示，上映6天以来，《南京照相馆》累计录得票房6.61 亿元（截至7月30日上午10时），观影总人次超1800万。其中，该片7月27日的票房为1.46亿元，这也打破了过去3年暑期档历史片单日票房纪录。 创新药持续活跃，辰欣药业（603367.SH）、东诚药业（002675.SZ）涨10%，华润双鹤（600062.SH）、浙江医药（600216.SH）、康辰药业（603590.SH） 均大涨。 中信证券研报称，目前创新药行业已经完成底部夯实，进入到真正的"临床价值重估"阶段，产业估值逻辑正 ...

Core Viewpoint - The biopharmaceutical sector experienced a notable increase of 1.77% on July 29, with San Yuan Gene leading the gains, reflecting positive market sentiment in this industry [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 3609.71, up by 0.33%, while the Shenzhen Component Index closed at 11289.41, up by 0.64% [1]. - Key stocks in the biopharmaceutical sector showed significant price increases, with San Yuan Gene rising by 20.76% to a closing price of 34.84, and Nuo Si Lan De increasing by 11.14% to 25.25 [1]. Group 2: Trading Volume and Value - San Yuan Gene had a trading volume of 143,900 shares, resulting in a transaction value of approximately 483 million yuan [1]. - Other notable stocks included Kang Chen Pharmaceutical with a closing price of 60.15, a rise of 7.93%, and a trading volume of 143,600 shares, leading to a transaction value of about 841 million yuan [1]. Group 3: Capital Flow - The biopharmaceutical sector saw a net inflow of 1.341 billion yuan from institutional investors, while retail investors experienced a net outflow of 1.318 billion yuan [2]. - The capital flow data indicates that institutional investors are showing confidence in the sector, while retail investors are withdrawing funds [2][3].

Summary of Kangchen Pharmaceutical Conference Call Company Overview - **Company**: Kangchen Pharmaceutical - **Core Product**: Suling, a snake venom-derived hemostatic agent, recognized for its unique properties and market performance since its launch in 2009 [2][5] Key Points Industry and Market Performance - **Suling Sales**: Expected to sell 11.5 million units in 2024, a slight decline but stabilizing in the second half of the year, with a target to return to a billion-level product by 2025 [2][7] - **Marketing Reform**: Transitioned from an alliance model to a self-operated model, showing significant effects with minimal revenue impact [2][7] Financial Health - **Cash Reserves**: Approximately 1 billion yuan in liquid assets, with a low debt-to-asset ratio of around 10%, providing financial support for future business expansion [2][9] Research and Development Pipeline - **Key Products**: - **ZY5,301**: For chronic pelvic pain, completed Phase III unblinding with positive data, currently in NDA discussions [2][4] - **K6 Inhibitor**: Leading global progress, Phase I clinical approval expected soon, aiming for Phase II initiation in late 2025 [3][16] - **EEXD and VJF Multi-target Inhibitors**: For advanced esophageal cancer, Phase III trials ongoing, with expectations for approval conditions by mid-2027 [2][17] Product Development Strategy - **New Product Launches**: Plans to introduce at least one new product annually, focusing on expanding the product pipeline [2][9] - **Pet Innovation Drug**: Development of Su Ying, a pet version of Suling for canine surgical hemostasis, addressing a market gap in veterinary medicine [2][6] Competitive Advantages - **Regulatory Recognition**: Products without insurance suffixes indicate higher recognition by insurance, enhancing clinical usage compliance [10] - **Academic Promotion**: Strong academic promotion capabilities, maintaining a focus on self-operated and academic sales strategies, differentiating from competitors [13][14] Future Outlook - **Sales Growth**: Anticipated recovery of Suling sales to a rapid growth trajectory in 2025, with ongoing marketing transformation efforts [2][7] - **Market Expansion**: Plans for mergers and acquisitions to achieve external growth and enhance product offerings [2][9] Clinical Trial Insights - **Esophageal Cancer Trials**: Targeting 490 patient enrollments for Phase III trials, currently at 200, with strategies to accelerate enrollment through expanded clinical centers [19][20] - **Survival Data**: Phase II trials show an overall survival (OS) of approximately 7.1 months, guiding future clinical quality assurance [21][22] Conclusion Kangchen Pharmaceutical is positioned for growth with a solid financial foundation, innovative product pipeline, and strategic marketing reforms aimed at enhancing market presence and operational efficiency. The focus on both human and veterinary medicine reflects a comprehensive approach to expanding its business scope and meeting diverse healthcare needs.